Literature DB >> 3864536

Ferritin--a tumor marker in myeloid leukemia.

E Aulbert, C G Schmidt.   

Abstract

High serum ferritin levels without any correspondence to the amount of total body storage iron have been found in patients with leukemia. Investigating 96 adults with different types of leukemia, we found that serum ferritin can be used as a tumor marker in myeloid leukemias. Extremely high serum ferritin levels were seen in acute myeloblastic leukemia before treatment and in blastic crisis of chronic myeloid leukemia (ie, 21-fold increased serum ferritin concentrations). Patients with acute myeloblastic leukemia in complete remission had their ferritin concentrations decreased to normal. A relapse of the disease was paralleled by a repeated increase of serum ferritin level. In patients with chronic myeloid leukemia during the chronic phase we found normal serum ferritin concentrations, whereas blast crisis was associated with highly raised serum ferritin levels. We conclude that serum ferritin concentration must be valued as a clinically useful tumor marker in these types of leukemia, exhibiting a helpful and simple parameter in monitoring the activity of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3864536

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  4 in total

Review 1.  The role of iron in tumour cell proliferation.

Authors:  Juan Luis Steegmann-Olmedillas
Journal:  Clin Transl Oncol       Date:  2011-02       Impact factor: 3.405

2.  Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment.

Authors:  Xin Li; Jun Lu; Hui Ren; Tianjun Chen; Lin Gao; Ligai DI; Zhucui Song; Ying Zhang; Tian Yang; Asmitananda Thakur; Shu-Feng Zhou; Yanhai Yin; Mingwei Chen
Journal:  Mol Clin Oncol       Date:  2012-09-19

Review 3.  The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Authors:  Sarah Weber; Anastasia Parmon; Nina Kurrle; Frank Schnütgen; Hubert Serve
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

4.  Iron overload phenotypes and HFE genotypes in white hemochromatosis and iron overload screening study participants without HFE p.C282Y/p.C282Y.

Authors:  James C Barton; J Clayborn Barton; Ronald T Acton
Journal:  PLoS One       Date:  2022-07-27       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.